Research Summary

Dr. Boyle is a translational scientist with research interests that include pediatric cancer therapeutics, pharmacokinetics, pharmacodynamics, pharmacogenomics, and clinical trial design. The majority of her research resides within the complex setting of hematopoietic cell transplantation (HCT) and is focused around chemotherapeutic and immunosuppressive agents used in the preparative regimens of pediatric HCT. Specifically, Dr. Boyle studies how covariates such as age, renal function, or genetic variants involved in drug metabolism or distribution may influence drug clearance in the pediatric HCT population.

Education

University of Minnesota, Minneapolis, BS, 2000, Biochemistry
University of Minnesota, Minneapolis, PharmD, 2006, Pharmacy
University of Minnesota, Minneapolis, PhD, 2009, Experimental and Clinical Pharmacology

Honors & Awards

  • 2010
    Early Career Research Award, Thrasher Pediatric Research Fund
  • 2011
    Travel Award for Early Career Researchers, UCSF Academic Senate
  • 2011
    Loan Repayment Recipient (2-year contract), National Institutes of Health Pediatric LRP
  • 2012
    Gary Rifkind Research Award for Junior Faculty, UCSF School of Pharmacy
  • 2013
    Loan Repayment Recipient (renewal, 2-year contract), National Institutes of Health Pediatric LRP
  • 2017
    Mid-Career Level Travel Award, UCSF Academic Senate

Selected Publications

  1. Nicolaides T, Hoogendijk R, Jaeger-Krause M, Dhall G, Goldman S, Gajjar A, Kilburn L, Leary S, Minturn J, Whipple N, Ramakrishnan D, Long-Boyle J, Aboian M, Prados M, Molinaro AM, Mueller S. Efficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAFV600E- or BRAFInsT-Mutant Brain Tumors: PNOC002. JCO Precis Oncol. 2026 Sep; 10(9):e2600558. View on PubMed
  2. Brooks J, Ismaeil S, Hughes MS, Apsel-Winger B, Lu Y, Huang L, Higham C, Nelson K, Long S, Gupta A, Lalefar NR, Anderson E, Pulsipher MA, Pai SY, Keizer RJ, Dvorak CC, Long-Boyle J. Prospective Evaluation of Thiotepa Pharmacokinetics in Children and Young Adults Undergoing Allogeneic or Autologous Hematopoietic Cell Transplantation. J Clin Pharmacol. 2026 Sep; 66(9):e70296. View on PubMed
  3. Dvorak CC, Collier W, Cho S, Holbrook-Brown L, Deimundo Roura C, Talano JA, Vatsayan A, Lalefar N, Anderson E, Olson T, Higham CS, Aguayo-Hiraldo P, Kapoor N, Waldhart JM, Odinakachukwu MC, Jacobsohn DA, Keizer RJ, Brooks J, Pulsipher MA, Long-Boyle JR. High Predicted Thiotepa Exposure is Associated with Increased Risk of Thrombotic Microangiopathy and Non-Relapse Mortality in Pediatric Patients Undergoing Alpha-Beta T-Cell Depleted Haploidentical Transplantation. Transplant Cell Ther. 2026 Aug 19. View on PubMed
  4. Dvorak CC, Avagyan S, Winestone LE, Salinas-Cisneros G, Chu JI, Higham CS, Pauerstein PT, Kharbanda S, Shimano KA, Huang JN, Long-Boyle JR. Rabbit Anti-Thymocyte Globulin Refractoriness or Induced Lymphocytosis in Alpha-Beta T-cell Depleted Hematopoietic Cell Transplant Recipients. Transplant Cell Ther. 2026 Aug 12. View on PubMed
  5. Muffly L, Lee CJ, Gandhi A, Varma A, Scott BL, Patel SS, Shiraz P, Youn M, Yanagiba C, Arulprakasam J, Le A, Kwon HS, Long-Boyle J, Shizuru JA, Pang WW, Artz AS. Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS. Blood. 2026 05 28; 147(22):2610-2620. View on PubMed
  6. Faulk KE, Kairalla JA, Hibbitts E, Long-Boyle J, Devidas M, August A, Gore L, Raetz E, Hunger SP, Loh ML, Teachey DT, Brown P, Breese EH, Kotecha RS, Guest E. Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1. Blood Adv. 2026 Jan 13; 10(1):70-74. View on PubMed
  7. Dvorak CC, Waters E, Temple WC, Salinas Cisneros G, Chu J, Winestone LE, Higham CS, Kharbanda S, Shimano KA, Avagyan S, Pauerstein P, Huang JN, Brooks JT, Long-Boyle JR. Fludarabine Pharmacokinetic Model-Based Dosing Minimizes the Risk of Graft Rejection in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2026 Apr; 32(4):476.e1-476.e14. View on PubMed
  8. Booth C, Sevilla J, Almarza E, Kuo CY, Zubicaray J, Terrazas D, O'Toole G, Chitty-Lopez M, Choi G, Nicoletti E, Long-Boyle J, Fernandes A, Chetty K, De Oliveira S, Banuelos C, Xu-Bayford J, Bastone AL, John-Neek P, Jackson C, Moore TB, Gilmour K, Schambach A, Rothe M, Kasbekar S, Rao GR, Patel K, Shah G, Thrasher AJ, Bueren JA, Schwartz JD, Kohn DB. Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1. Obstet Gynecol Surv. 2025 Nov 01; 80(11):687-689. View on PubMed
  9. Apsel Winger B, Polli JW, Long-Boyle J, Weber A, Brooks J, Parikh J, Damian V. Prediction of neutrophil nadir and recovery following paediatric haematopoietic cell transplantation with busulfan conditioning. Br J Clin Pharmacol. 2026 Feb; 92(2):568-578. View on PubMed
  10. Agarwal R, Bertaina A, Soco C, Long-Boyle JR, Saini G, Kunte N, Hiroshima L, Chan YY, Willner H, Krampf MR, Nofal R, Barbarito G, Sen S, Van Hentenryck M, Walck E, Scheck A, Perriman RJ, Bouge A, Istomina E, Din HN, Klinger EF, Cheng JC, Wlodarski MW, Boelens JJ, Shizuru JA, Pang WW, Weinberg K, Parkman R, Roncarolo MG, Porteus M, Czechowicz A. Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial. Nat Med. 2025 Sep; 31(9):3183-3190. View on PubMed
  11. Booth C, Sevilla J, Almarza E, Kuo CY, Zubicaray J, Terrazas D, O'Toole G, Chitty-Lopez M, Choi G, Nicoletti E, Long-Boyle J, Fernandes A, Chetty K, De Oliveira S, Banuelos C, Xu-Bayford J, Bastone AL, John-Neek P, Jackson C, Moore TB, Gilmour K, Schambach A, Rothe M, Kasbekar S, Rao GR, Patel K, Shah G, Thrasher AJ, Bueren JA, Schwartz JD, Kohn DB. Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1. N Engl J Med. 2025 May 01; 392(17):1698-1709. View on PubMed
  12. Choi JE, Valle R, Long-Boyle J, Garcia BM, Frieden IJ, Pincus LB, Akagi N, Bhargava P, Wen KW, Ozgediz D, Rangaswami A, Chu J, Levinson A, Avagyan S. KIT Inhibitor Therapy in a Pediatric Patient With Systemic Mastocytosis and a Germ Cell Tumor of Shared Clonal Origin. Pediatr Blood Cancer. 2025 Jul; 72(7):e31717. View on PubMed
  13. Dvorak CC, Cho S, Salinas Cisneros G, Higham CS, Chu J, Winestone LE, Temple WC, Kharbanda S, Shimano KA, Avagyan S, Pauerstein PT, Huang JN, Cheng G, Lalefar N, Aguayo-Hiraldo P, Keizer RJ, Pulsipher MA, Long-Boyle JR. High Melphalan Exposure Increases the Risk of Graft-Versus-Host Disease in Pediatric Patients Undergoing Alpha-Beta T-Cell Depleted Haploidentical Transplantation. Transplant Cell Ther. 2025 Jun; 31(6):384.e1-384.e15. View on PubMed
  14. Dvorak CC, Temple WC, Cisneros GS, Chu J, Winestone LE, Higham CS, Shimano KA, Kharbanda S, Avagyan S, Pauerstein P, Huang JN, Cheng G, Waters E, Winger BA, Cowan MJ, Long-Boyle JR. Younger children with nonmalignant disease have increased incidence of mixed myeloid chimerism after allogeneic hematopoietic cell transplantation with busulfan-based conditioning. Transplant Cell Ther. 2025 Apr; 31(4):259.e1-259.e15. View on PubMed
  15. Dvorak CC, Long-Boyle JR, Holbrook-Brown L, Abdel-Azim H, Bertaina A, Vatsayan A, Talano JA, Bunin N, Anderson E, Flower A, Lalefar N, Higham CS, Kapoor N, Klein O, Odinakachukwu MC, Cho S, Jacobsohn DA, Collier W, Pulsipher MA. Effect of rabbit ATG PK on outcomes after TCR-αβ/CD19-depleted pediatric haploidentical HCT for hematologic malignancy. Blood Adv. 2024 Dec 10; 8(23):6003-6014. View on PubMed
  16. Mike JK, White Y, Ha J, Iranmahboub A, Hawkins C, Hutchings RS, Vento C, Manzoor H, Wang A, Goudy BD, Vali P, Lakshminrusimha S, Gobburu JVS, Long-Boyle J, Fineman JR, Ferriero DM, Maltepe E. Perinatal Caffeine Administration Improves Outcomes in an Ovine Model of Neonatal Hypoxia-Ischemia. Stroke. 2024 11; 55(11):2705-2715. View on PubMed
  17. Bognàr T, Garcia-Rosa M, Lalmohamed A, Güngör T, Hauri-Hohl M, Prockop S, Oram L, Pai SY, Brooks J, Savic RM, Dvorak CC, Long-Boyle JR, Krajinovic M, Bittencourt H, Teyssier AC, Théorêt Y, Martinez C, Egberts TCG, Morales E, Slatter M, Cuvelier GDE, Chiesa R, Wynn RF, Coussons M, Cicalese MP, Ansari M, Long SE, Ebens CL, Lust H, Chaudhury S, Nath CE, Shaw PJ, Keogh SJ, van der Stoep MYEC, Bredius R, Lindemans CA, Boelens JJ, Bartelink IH. Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity. Blood Adv. 2024 10 08; 8(19):5137-5145. View on PubMed
  18. Jung D, Long-Boyle JR, Pang WW, Gobburu JVS. Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia. Transplant Cell Ther. 2024 09; 30(9):923.e1-923.e9. View on PubMed
  19. Higham CS, Shimano KA, Kharbanda S, Chu J, Cisneros GS, Winestone LE, Dara J, Huang JN, Hermiston ML, Long-Boyle JR, Dvorak CC. Cyclophosphamide and Thiotepa Increases Risk of Transplant-Associated Thrombotic Microangiopathy. Transplant Cell Ther. 2024 09; 30(9):931.e1-931.e10. View on PubMed
  20. Salinas Cisneros G, Dvorak CC, Long-Boyle J, Kharbanda S, Shimano KA, Melton A, Chu J, Winestone LE, Dara J, Huang JN, Hermiston ML, Zinter M, Higham CS. Diagnosing and Grading of Sinusoidal Obstructive Syndrome after Hematopoietic Stem Cell Transplant of Children, Adolescent and Young Adults treated in a Pediatric Institution with Pediatric Protocols. Transplant Cell Ther. 2024 07; 30(7):690.e1-690.e16. View on PubMed

Go to UCSF Profiles, powered by CTSI